Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: Its involvement in neurotransmitter metabolite clearance from the brain

Journal of Neurochemistry

Volumn 83, Issue 1, 2002, Pages 57-66

  Ohtsuki, Sumio ^a,b   Asaba, Hiroshi ^a   Takanaga, Hitomi ^a,b   Deguchi, Tsuneo ^a,c   Hosoya, Ken Ichi ^b,d   Otagiri, Masaki ^c   Terasaki, Tetsuya ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b Japan Science and Technology Agency   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Blood brain barrier; Efflux transport; Indoxyl sulfate; Organic anion transporter 3 (OAT3); Uremic toxin

Indexed keywords

3 (3 CARBOXY 4 METHYL 5 PROPYL 2 FURYL)PROPIONIC ACID; 4 AMINOHIPPURIC ACID; ACICLOVIR; BACLOFEN; BENZOIC ACID; CARRIER PROTEIN; CEFAZOLIN; CIMETIDINE; HIPPURIC ACID; HOMOVANILLIC ACID; INDICAN; KETOPROFEN; MERCAPTOPURINE; MESSENGER RNA; NEUROTRANSMITTER; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; PROBENECID; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UREMIC TOXIN; VANILMANDELIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIUM; CLEARANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY DYSFUNCTION; MALE; METABOLITE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOPUS;

ANIMALS; ANTIMETABOLITES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GABA AGONISTS; HOMOVANILLIC ACID; INDICAN; MALE; MICROINJECTIONS; NEUROTRANSMITTER AGENTS; OOCYTES; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-AMINOHIPPURIC ACID; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UREMIA; XENOPUS LAEVIS;

ANIMALIA;

EID: 0036788234     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01108.x     Document Type: Article

References (47)

1. Abe T., Kakyo M., Sakagami H., Tokui T., Nishio T., Tanemoto M., Nomura H., Hebert S. C., Matsuno S., Kondo H. and Yawo H. (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J. Biol. Chem. 273, 22395-22401.
2. Almond M. K., Fan S., Dhillon S., Pollock A. M. and Raftery M. J. (1995) Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. Nephron 69, 428-432.
3. Apiwattanakul N., Sekine T., Chairoungdua A., Kanai Y., Nakajima N., Sophasan S. and Endou H. (1999) Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. 55, 847-854.
4. Boumendil-Podevine E. F., Podevine R. A. and Richet G. (1975) Uricosuric agents in uremic sera. J. Clin. Invest. 55, 1142-1152.
5. Burke W. J., Li S. W., Schmitt C. A., Xia P., Chung H. D. and Gillespie K. N. (1999) Accumulation of 3,4-dihydoxyphenylglycoaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res. 816, 633-637.
6. Cha S. H., Sekine T., Kusuhara H., Yu E., Kim J. Y., Kim D. K., Sugiyama Y., Kanai Y. and Endou H. (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 275, 4507-4512.
7. Deguchi Y., Hayashi H., Fujii S., Naito T., Yokoyama Y., Yamada S. and Kimura R. (2000b) Improved brain delivery of a nonsteroidal antiinflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. J. Drug Targeting 8, 371-381.
8. Deguchi Y., Inaba K., Tomiyasu K., Nozawa K., Yamada S. and Kimura R. (1995) Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharm. Res. 12, 1838-1844.
9. Deguchi Y., Nozawa K., Yamada S., Yokoyama Y. and Kimura R. (1997) Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. J. Pharmacol. Exp. Ther. 280, 551-560.
10. Deguchi Y., Yokoyama Y., Nozawa K., Yamada S. and Kimura R. (2000a) Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci. 66, 649-662.
11. Emanuelsson B. M., Paalzow L. and Sunzel M. (1987) Probenecid-induced accumulation of 5-hydroxyindoleacetic acid and homovanillic acid in rat brain. J. Pharm. Pharmacol. 39, 705-710.
12. Feng B., Dresser M. J., Shu Y., Johns S. J. and Giacomini K. M. (2001) Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. Biochemistry 40, 5511-5520.
13. Fletcher C. V., Chinnock B. J., Chace B. and Balfour H. H. (1988) Pharmacokinetics and safty of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. Clin. Pharmacol. Ther. 44, 158-163.
14. Gao B., Stieger B., Noé B., Fritschy J. M. and Meier P. J. (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J. Histochem. Cytochem. 47, 1255-1263.
15. Goldin A. (1992) Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol. 207, 266-279.
16. Hosoya K., Sugawara M., Asaba H. and Terasaki T. (1999) Blood-brain barrier produces significant efflux of L-aspartic acid, but not D-aspartic acid: in vivo evidence using the Brain Efflux Index method. J. Neurochem. 73, 1206-1211.
17. Hosoya K., Takashima T., Tetsuka K., Nagura T., Ohtsuki S., Takanaga H., Ueda M., Yanai N., Obinata M. and Terasaki T. (2000) mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J. Drug Targeting 8, 357-370.
18. Inui K., Masuda S. and Saito H. (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58, 944-958.
19. Kakee A., Takanaga H., Hosoya K., Sugiyama Y. and Terasaki T. (2002) In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. Microvasc. Res. 63, 233-238.
20. Kakee A., Terasaki T. and Sugiyama Y. (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277, 1550-1559.
21. Kakee A., Terasaki T. and Sugiyama Y. (1997) Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the Brain Efflux Index method. J. Pharmacol. Exp. Ther. 283, 1018-1025.
22. Kusuhara H., Sekine T., Utsunomiya-Tata N., Tsuda M., Kojima R., Cha S. H., Sugiyama Y., Kanai Y. and Endou H. (1999) Molecular cloning and characterization of a new mutispecific organic anion transporter from rat brain. J. Biol. Chem. 274, 13675-13680.
23. Lamensdorf I., Eisenhofer G., Harvey-White J., Hayakawa Y., Kirk K. and Kopin I. J. (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J. Neurosci. Res. 60, 552-558.
24. Li J. Y., Boado R. J. and Pardridge W. M. (2001) Blood-brain barrier genomics. J. Cereb. Blood Flow Metab. 21, 61-68.
25. Lim C. F., Bernard B. F., de Jong M., Docter R., Krenning E. P. and Hennemann G. (1993) A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J. Clin. Endocrinol. Metab. 76, 318-324.
26. Morita N., Kusuhara H., Sekine T., Endou H. and Sugiyama Y. (2001) Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 298, 1179-1184.
27. Morrison P. F., Morishige G. M., Beagles K. E. and Heyes M. P. (1999) Quinolinic acid is extruded from the brain by a probenecid-sensitive carrier system: a quantitative analysis. J. Neurochem. 72, 2135-2144.
28. Müting D. (1965) Studies on the pathogenesis of uremia: omparative determinations of glucuronic acid, indican, free and bound phenols in the serum, cerebrospinal fluid, and urine of renal disease with and without uremia. Clin. Chim. Acta 12, 551-554.
29. Nakada Y., Yamamoto K., Kawakami J., Sawada Y. and Iga T. (1995) Effect of acute renal failure on neurotoxicity of cimetidine in rats. Pharm. Res. 12, 1953-1957.
30. Niwa T. (1996) Organic acids and uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin. Nephrol. 16, 167-182.
31. Niwa T. and Ise M. (1994) Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124, 96-104.
32. Niwa T., Ise M. and Miyazaki T. (1994) Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am. J. Nephrol. 14, 207-212.
33. Noé B., Hagenbuch B., Stieger B. and Meier P. J. (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. USA 94, 10346-10350.
34. Porter R. D., Cathcart-Rake W. F., Wan S. H., Whittier F. C. and Grantham J. J. (1975) Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. J. Lab. Clin. Med. 85, 723-731.
35. Sakai T., Maruyama T., Imamura H., Shimada H. and Otagiri M. (1996) Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. J. Pharmacol. Exp. Ther. 278, 786-792.
36. Schliamser S. E., Cars O. and Norrby S. R. (1991) Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis. J. Antimicrob. Chemother 27, 405-425.
37. Schoots A. C., De Vries P. M., Thiemann R., Hazejager W. A., Visser S. L. and Oe P. L. (1989) Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin. Chim. Acta 185, 91-107.
38. Sekine T., Cha S. H., Tsuda M., Apiwattanakul N., Nakajima N., Kanai Y. and Endou H. (1998) Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 429, 179-182.
39. Sekine T., Watanabe N., Hosoyamada M., Kanai Y. and Endou H. (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272, 18526-18529.
40. Sugiyama D., Kusuhara H., Shitara Y., Abe T., Meier P. J., Sekine T., Endou H., Suzuki H. and Sugiyama Y. (2001) Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther. 298, 316-322.
41. Sullivan P. A., Murnaghan D., Callaghan N., Kantamaneni B. D. and Curzon G. (1980) Effect of dialysis on plasma and CSF tryptophan and CSF 5-hydroxyindoleacetic acid in advanced renal disease. J. Neurol. Neurosurg. Psychiatry. 43, 739-743.
42. Sweet D. H., Wolff N. A. and Pritchard J. B. (1997) Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272, 30088-30095.
43. Terasaki T. and Hosoya K. (1999) The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv. Drug Deliv. Rev. 36, 195-209.
44. Terasaki T. and Hosoya K. (2001) Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol. Pharm. Bull. 24, 111-118.
45. Tsutsumi Y., Maruyama T., Takadate A., Shimada H. and Otagiri M. (2000) Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 85, 60-64.
46. Uwai Y., Okuda M., Takami K., Hashimoto Y. and Inui K. (1998) Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 438, 321-324.
47. Yamaoka K., Tanigawara Y., Nakagawa T. and Uno T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio. Dyn. 4, 879-885.